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During the last few years, significant progress has been made in the adjuvant chemother-
apy of primary breast cancer. When compared with anthracycline-based regimens, the
addition of taxanes significantly improved disease-free survival and overall survival, and
some studies suggest that many women could be treated without anthracyclines. In
patients with HER2-positive tumours, adjuvant trastuzumab produced a significant reduc-
tion of mortality and recurrence in comparison with no adjuvant trastuzumab.
Despite these dramatic achievements in the treatment of early breast cancer, several
questions remain to be answered, and individualisation of adjuvant therapy should be fur-
ther improved. In this regard, the application of new technologies (i.e. genomics and pro-
teomics) may be of great value.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
In the adjuvant treatment of primary breast cancer, the Ox-
ford Overview showed that combination chemotherapy was
more effective than single agents, that 4–6 months of treat-
ment using the same regimen produced optimal benefit, that
regimens containing an anthracycline were superior to regi-
mens lacking anthracyclines and that for women with hor-
mone receptor-positive breast cancer, the combination in
sequence of chemotherapy and endocrine therapy provided
an additive benefit.1
During the last years, other clinical trials have addressed a
number of new questions related to the adjuvant chemother-
apy of breast cancer, including the role of taxanes and the va-
lue of dose-dense administration of chemotherapy. At the
same time, the exciting results obtained with trastuzumab
in patients with HER2-positive metastatic breast cancer led
to a new generation of adjuvant trials in this subset of pa-
tients, whose results, whilst confirming the beneficial effects
of trastuzumab-based treatment in the adjuvant setting,er Ltd. All rights reserved
; fax: +39 06 52665075.raised several important questions regarding the optimal
administration of treatment and the related toxicity.
Despite these important achievements, overtreatment with
consequentadverseeventsandcosts iscommonin theadjuvant
breast cancer setting, because of the lack of an accuratemethod
of identification of patients at real risk of relapse. Fortunately, in
the recent years, significant improvement in the understanding
ofmolecular biologyof breast cancer has opened theway to bet-
ter define subsets of patientswith different prognoses and drug
sensitivities, and thiswill hopefully allow to improveour clinical
decision making in early breast cancer.
We will summarise some of the most important advances
in the adjuvant chemotherapy of patients with primary breast
cancer, particularly those with HER2-positive tumours.
2 Adjuvant chemotherapy
The latest Oxford Overview demonstrated that adjuvant
chemotherapy significantly reduced the risk of recurrence
and death in women with operable breast cancer, regardless.
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menopausal status. Anthracycline-containing regimens were
generally more effective than earlier combinations of cyclo-
phosphamide (C), methotrexate (M) and fluorouracil (F).
In fact, the absolute difference of recurrence and breast
cancer mortality between anthracycline-based and CMF che-
motherapy was about 3% at 5 years and 4% at 10 years.
Anthracycline-containing regimens included doxorubicin (A)
or epirubicin (E), and were generally given for about 6 months
with other cytotoxic agents (e.g. FAC or FEC). They became the
standard adjuvant therapy for the majority of patients with
operable breast cancer, as well as the reference treatment
for comparison in trials using new chemotherapy regimens.
In an attempt to improve the treatment results, several
randomised trials evaluated the effects of taxanes in combina-
tion or in sequence with anthracycline-containing regimens.
Generally, these trials showed significant longer disease-
free survival (DFS) for the taxane arms, but only rarely a clear
advantage in overall survival (OS) was evidenced. This was
observed in a recent meta-analysis evaluating 13 randomised
trials including 22,903 patients.2 The pooled HR estimate was
0.83 (p < 0.001) for OS, and the risk reduction was not influ-
enced by type of taxane (paclitaxel or docetaxel), oestrogen
receptor (ER) expression, number of metastatic lymph nodes
and patient’s age/menopausal status. The use of a taxane re-
sulted in an absolute 5-year risk reduction of 5% for DFS and
3% for OS. The administration schedule, concomitant or
sequential, did not seem to influence outcome.
The specific issue of schedule was recently addressed by
the BIG 02-98 trial testing the incorporation of docetaxel (T)
into anthracycline-based adjuvant regimens and companing
sequential versus concurrent schedules.3 Patients (n = 2887)
with node-positive breast cancer were randomised to four
arms: sequential control (4 A! 3 CMF); concurrent control (4
AC! 3 CMF); sequential T (3 A! 3 T! 3 CMF); concurrent T
(4 AT! 3 CMF). DFS was better in the sequential T arm than
in the sequential control arms (HR = 0.79, p = 0.0035), whereas
it was similar in the two concurrent arm (HR = 0.93, p = 0.48).
Moreover, the sequential T arm had a slightly better DFS in
comparison with the concurrent T arm (HR = 0.83). Subgroup
analysis did not showany evidence of different effectswith re-
gard to efficacy of T according to age, lymph node status and
hormonal receptor status. Additional follow-up will be re-
quired to evaluate wether a statistically significant difference
in OS will emerge. The higher DFS observed in the sequential
Tarm comparedwith concurrent Tarmmay be a consequence
of a dose–response relationship, a higher anthracycline cumu-
lative dose, a longer duration of treatment or a lack of chemo-
resistance development due to the sequential drug use
according to the Norton-Simon hypothesis.
In an attempt to avoid the cardiac toxicity related to
anthracycline administration, the US Oncology group has
run a prospective randomised trial to compare 4 cycles of
AC with a non-anthracycline regimen of 4 cycles of docetaxel
and cyclophosphamide (TC) in 1016 node-positive and high-
risk node-negative breast cancer patients.4 After a median
follow-up of 7 years, patients treated with TC had a statisti-
cally significant improvement in DFS in comparison with
those treated with AC (81% versus 75%). Overall survival for
patients in TC arm was 87%, compared with 82% for womentreated with AC, which was a statistically significant
difference.53. Adjuvant therapy in HER2-positive patients
Considering the benefit of trastuzumab-based regimens in
advanced breast cancer, five prospective randomised trials
(NSABP – B31, NCCTG N9831, HERA, BCIRG 006 and FinHer)
have recently been completed and early results have been
published, all demonstrating a significant benefit in patients
receiving trastuzumab.
A recent meta-analysis of these five randomised trials
showed a significant reduction of mortality (p < 0.00001),
recurrence (p < 0.00001) and metastases rates (p > 0.00001) in
favour of trastuzumab-containing regimens. There weremore
grade III or IV cardiac toxicity after trastuzumab (4.5%) versus
no trastuzumab (1.8%). The likelihood of cardiac toxicity was
2.45-fold higher in trastuzumab arms, but this result was
associated with heterogeneity.6
The issue of cardiac toxicity in adjuvant trials using regi-
mens including anthracyclines and trastuzumab has received
a great attention.
All patients enrolled in the five adjuvant trastuzumab tri-
als were subject to prospective cardiac monitoring. Both the
B-31 and N9831 trials assessed the incidence of NYHA class
III/IV cardiac heart failure (CHF) or cardiac death. In the recent
update of the N9831 trial, the 3-year incidence of CHF was
0.3%, 2.8%, 3.3% in the control, sequential and concurrent
trastuzumab arm, respectively.7 In the B-31 trial this toxicity
occurred in 0.8% of the control arm and in 4.1% of the trast-
uzumab arm.
In the BCIRG 006 trial, a NYHA grade III/IV CHF was ob-
served in 1.8% of the patients in the AC! TH arm, and in
0.3% of the patients treated with AC! T or TCH, the arm
not including an anthracycline (AC! TH versus TCH,
p < 0.0015).
In the HERA trial, after 2 years of follow-up, the incidence
of NYHA Class III/IV CHF in the 1-year trastuzumab arm was
0.6% compared with 0.0% in the control arm, whilst a symp-
tomatic CHF was recorded in 2% versus 0.1% of the patients
(p < 0.0001).8
No significant cardiotoxicity has been reported in the
small FinHer trial.
The overall risk of severe CHF reported in HERA trial was
lower than that in B-31 or N9831, and one of the possible
explanation might be the longer interval between discontinu-
ing anthracyclines and starting trastuzumab. The mechanism
of cardiac dysfunction associated with trastuzumab is not
clearly understood. Cardiomyocyte injury from anthracy-
clines is thought to be mediated through free-radical injury,
resulting in permanent ultrastructural changes and poor cel-
lular and clinical reversibility. Trastuzumab cardiac damage
might occur through triggering myocyte apoptosis and abro-
gating mitochondrial function by activation of the mitochon-
drial apoptotic pathway through the BCL–X proteins, lowering
ATP levels and causing subsequent contractile dysfunction.9
Current data suggest that trastuzumab cardiotoxicity can be
reverted by discontinuing trastuzumab and initiating stan-
dard cardiological care.
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mal trastuzumab administration in adjuvant treatment of
breast cancer, including the optimal timing of initiation in
patients who have completed adjuvant chemotherapy, the
relative effectiveness of simultaneous and sequential admin-
istration with other chemotherapeutic agents, and whether
there is a subgroup of patients in whom chemotherapy is
not mandatory. Optimum adjuvant trastuzumab duration re-
mains to be established by randomised trials, although the
FinHer trial suggests that a short trastuzumab administration
is effective, and further data will be available from the 2-year
trastuzumab arm of the HERA trial.
To avoid treatment cardiotoxicity, the use of non-anthra-
cycline containing regimens has been suggested, due to the
results of BCIRG 006 trial indicating similar efficacy for TCH
and AC! TH treatments, with less cardiotoxicity for the
non-anthracycline arm. In this regard, of great interest is
the possibility of a ‘targeted’ anthracycline use. The topoiso-
merase 2A (TOPO 2A) gene is often co-amplified with HER2
gene (30–90% of cases), whilst it is rarely amplified (5–10%)
in HER2 non-amplified tumours. The TOPO 2A gene product
is an enzyme which is a major target for anthracyclines. A
recent analysis of the BCIRG 006 trial compared efficacy of
treatment in TOPO2–HER2 co-amplified tumours with non-
co-amplified tumours, and found that co-amplified tumours
(35% of the total) had significantly improved DFS compared
with non-co-amplified tumours.10 In non-co-amplified
tumours, a DFS advantage was observed in the trast-
uzumab-containing arms (AC! TH and TCH) versus the con-
trol arm (AC! T). These data indicate the possibility of
omitting anthracyclines in non-co-amplified tumours, thus
reducing the cardiac risk. Nevertheless, further prospective
studies are needed to confirm these findings.4. Conclusions and future perspectives
The results of several large randomised trials and meta-anal-
yses have showed a substantial benefit from adjuvant chemo-
therapy in women with operable breast cancer, in terms of
both disease recurrence and survival. The use of targeted
drugs, such as trastuzumab, has led to a major contribution
in improving treatment results in specific subsets of patients.
However, the individualisation of adjuvant treatment should
be further improved. In this regard, the application of new
technologies (i.e. genomics and proteomics) may be of great
value.
Genomic profiling of breast cancer is already being em-
ployed in the adjuvant setting, and various genomic profiles
are under clinical development as predictors of tumour sensi-
tivity to specific treatments, such as tamoxifen, taxanes, FAC
and AC.It is hoped that the ongoing studies and a better molecular
characterisation of the disease will lead the clinicians to-
wards more specific treatment options for patients with oper-
able breast cancer.
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